Execution of a share buyback agreement for up to €2 billion Paris, February 7, 2025. On January 30, 2025 ( Sanofi ...

Response Pharmaceuticals, Inc., a clinical-stage company focused on weight management and metabolic health in high-risk populations, today announced the early completion of enrollment in a Phase 2 ...

Execution of a share buyback agreement for up to €2 billion Paris, February 7, 2025. On January 30, 2025, Sanofi announced its intention to execute a share buyback program in 2025 of €5 billion, ...

San Diegan biotech Viking Therapeutics (Nasdaq: VKTX) has announced plans to initiate late-stage clinical trials for its ...

AstraZeneca reports mixed results in the fourth quarter. It gains in pre-market after assuring investors that the business impact of the Chinese investigations remains minor.

The US Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for brensocatib for patients with ...

Kura Oncology and Japan’s Kyowa Kirin have announced that their menin inhibitor ziftomenib met the primary endpoint in a ...

Shares in US retinal diseases specialist EyePoint Pharmaceuticals recovered from an early nosedive to close trading marginally higher on Wednesday.

California, USA-based rare disease company Ultragenyx Pharmaceutical yesterday released new data demonstrating treatment with UX111 (ABO-102) AAV gene therapy led to a statistically-significant ...

US health technology assessor the Institute for Clinical and Economic Review (ICER) yesterday posted its revised Evidence Report assessing the comparative clinical effectiveness and value of ...

The New England Journal of Medicine has published results from the Phase II eNRGy trial for Bizengri (zenocutuzumab), a novel cancer med from Merus. Bizengri is the first approved treatment for people ...

Solid +5.1% Growth in a Challenging Context Record Results, Reaching 20% Operating Margin Sales: 43.48 billion euros, +5.6% reported and +5.1% like-for-like1. Another year of outperformance in a norma ...